January 2016 in “e-Oftalmo CBO Revista Digital de Oftalmologia” CSC is linked to mineralocorticoid receptor damage, stress, and steroid use, with treatments including drugs and laser therapies to prevent eye damage.
2 citations
,
January 2016 Rat hair follicle stem cells can be successfully cultured and may be useful for creating tissue-engineered hair, vessels, and skin.
November 2022 in “Journal of Investigative Dermatology” Short-term treatment with ROCKi increases skin cell growth without changing stem cell features.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
January 2026 in “International Journal of Dermatology” Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
3 citations
,
September 2015 in “Journal of Vascular Surgery” Chemical lumbar sympathectomy is an effective and safe treatment for idiopathic livedo reticularis.
5 citations
,
February 2025 in “Pediatric Dermatology” Ritlecitinib was generally well tolerated in children with alopecia areata.
January 2024 in “Genetics in Medicine Open” Adults with Tatton-Brown-Rahman syndrome may have serious heart problems and need lifelong heart monitoring.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
May 2023 in “Experimental Dermatology” RCM and OCT are effective for diagnosing and monitoring hair-related skin diseases but lack standardized protocols and need more research.
The treatment improved facial structure and corrected bite issues in patients.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
5 citations
,
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” The gene therapy showed significant wound healing and was safe for treating severe RDEB.
11 citations
,
November 2018 in “British Journal of Dermatology” Oxymetazoline cream 1.0% effectively reduces rosacea redness, and using baseline photos improves assessment accuracy.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
More research is needed to confirm the long-term effects of oral drugs for chronic central serous chorioretinopathy.
36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
September 2025 in “Cureus” There is no standard treatment for CCCA, and practices vary widely.
January 2023 in “Cutaneous and Ocular Toxicology”
April 2023 in “Journal of Investigative Dermatology” Acne patients have higher skin mTORC1 activity, which is reduced by isotretinoin treatment.
15 citations
,
July 2020 in “Applied Sciences” PRS injections can improve knee function and reduce pain for up to a year.
87 citations
,
December 2015 in “Cochrane library” No single treatment is clearly effective for central serous chorioretinopathy.